KRAS and neoplasm: However, in a randomised, open-label phase II trial comparing afatinib with cetuximab in patients with mCRC, afatinib demonstrated inferior efficacy to cetuximab in KRAS wild-type tumours, and only modest disease control in KRAS-mutated tumours [134].